ABBV250502P197500
- 5.40
- -6.52-54.70%
AbbVie Newsroom
Netflix, Sherwin-Williams, AbbVie And More On CNBC's 'Final Trades'
FDA Approves AbbVie's Upadacitinib for Giant Cell Arteritis
May's Must-See Financial Events: Apple & Nvidia Earnings, Berkshire Meeting, Interest Rate Decision, and More
Guggenheim Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $216
Allergan Aesthetics Announces Inaugural Allergan Medical Institute (AMI) Training Centers Faculty
Express News | CNBC Halftime Report Final Trades: Netflix, AbbVie, IShares U.S. Industrials, Sherwin-Williams Company
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Buy Alphabet And AbbVie
A Quick Look at Today's Ratings for AbbVie(ABBV.US), With a Forecast Between $204 to $227
AbbVie Is Maintained at Buy by Guggenheim
Today's Analyst Rating | UBS Cuts Its Price Target Cut on Amazon to $253, Meta Platforms Price Target Raised to $695 by Loop Capital
Abbvie: FDA Approves RINVOQ, 15 Mg, Once Daily, For Treatment Of Adults With Giant Cell Arteritis
Express News | Rinvoq® (Upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (Gca)
Express News | Abbvie : Guggenheim Raises Target Price to $216 From $214
Warren Buffett's 60-Year Legacy: What to Watch for at Berkshire Hathaway Shareholders Meeting?
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (IRWD), AbbVie (ABBV) and Molecular Partners (MOLN)
RINVOQ (Upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
Why AbbVie Stock Trounced the Market Today
S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report
AbbVie Inc. Stock Rallies 3.4%, Outperforms Competitors